Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
Feb 20, 2024 | Alternative Reimbursement Strategies, Announcements, Benchmarks, Benefits preservation, Fair market reimbursement, MedBen University, Pharmacogenomics, Precision medicine, Roundtables, Specialty Drugs, Trend
MedBen University (MBU) is in session, so mark your calendar! As we mentioned in the last e-briefs, MBU launched its 23rd season last month with the Benefits Advisory Conference for brokers… and this Spring, MBU will be conducting two employer roundtables:...
Feb 6, 2024 | Claims, Claims data, Cost Savings, Drug costs, Gene therapy, Genetic testing, MedBen News, MedBen Rx, MedBen University, Pharmacogenics, Pharmacy Benefits Manager (PBM), Self-funding, Specialty Drugs, Stop-Loss
MedBen recently had the honor to welcome some of the most respected names in the benefits management industry. At the invitation-only 2024 Benefits Advisory Conference on January 26, attending brokers learned about health plan innovations that will help self-funded...
Jan 22, 2024 | Access solutions, Benefits preservation, MedBen Rx, Pharmacy, Prescription, Specialty Drugs
A recent Segal Health Plan Cost Trend Survey projects 2024 cost trend for prescription drugs to approach 10%… but specialty drug trend alone may reach 15% this year, as increased use of expensive drugs continues to drive costs up. (We’ve actually seen...
Jan 5, 2024 | Access solutions, Acquisition Cost Index (ACI) pricing, Appropriateness Solutions, Benefits preservation, Comparative Effectiveness, Drug costs, MedBen Rx, Pricing solutions, Specialty Drugs
Pfizer, Sanofi, Takeda Pharmaceutical, and other drugmakers will raise the prices of more than 500 drugs in early January, according to an analysis by health care researchers 3 Axis Advisors. Inflation and rising manufacturing costs will contribute to the price...
Aug 7, 2023 | Access solutions, Case Studies, Cost Savings, Drug costs, Limited use HRA, MedBen Rx, Patient advocacy program, Pharmacy, Rx Costs, Savings, Specialty Drugs
With specialty drugs now making up about half of total drug spending – and poised to go even higher as more new specialty drugs roll out every year – the need for workable access solutions grows. Fortunately, MedBen Rx has them. Our unique approach incorporates a...
